War against respiratory syncytial virus

Harbi, Adel S. Al

doi:10.15537/smj.2018.12.23355

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No prophylactic treatment with palivizumab was previously provided to any of the study participants. In 2018, palivizumab was recommended by the Saudi authority to be used for infants based on the gestational age at birth, body weight, and comorbidities (chronic lung disease and congenital heart disease) [19]. No such risk factors were reported in our study population.…”

Section: Discussionmentioning

confidence: 81%

The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic

Alkharsah

2022

Medicina

View full text Add to dashboard Cite

Background and Objectives: Respiratory syncytial virus (RSV) is a major cause of morbidity and hospital admission due to respiratory tract infection among infants and young children. The current study aims to describe the prevalence and the seasonal pattern of RSV during the previous seven years. Materials and Methods: Clinical data and RSV antigen and PCR test results were collected from patients’ medical records at King Fahd Hospital of the University in the Eastern Province of Saudi Arabia between January 2015 and February 2022. Results: The overall percentage of RSV detection was 26.3% (336/1279) among the tested individuals. RSV infection was more common among children below five years and elderly above 60 years of age. Two-thirds of the cases required hospitalization. The average hospital stay due to RSV infection was 6.5 days (range 0–56 days). The rate of hospitalization was higher among infants and younger children and decreased with age (p-value < 0.001). RSV infection was more prevalent between August and February and decreased appreciably between March and July. The peak level of infection was during December and January. No RSV infections were reported during the COVID-19 pandemic and the following winter. The cases increased again in August 2021, with an unusual out-of-season peak. Conclusions: RSV infection is one of the important causes of morbidity and hospitalization among infants and young children in Saudi Arabia. The seasonal pattern of infection has changed after the COVID-19 pandemic, and the physicians should be aware that infection may happen currently at different times throughout the year.

show abstract

Section: Discussionmentioning

confidence: 81%

The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic

Alkharsah

2022

Medicina

View full text Add to dashboard Cite

show abstract

“…The estimated incidence rate was 7.6% [20] , and the test positivity was 10% in the RSV-specific age group [21] .…”

Section: Resultsmentioning

confidence: 93%

“…During the screening phase, the inputs considered for the model were as follows: country population, test positivity rate, incidence rate, and the proportion of patients in the patient-specific age group for the condition [17] , [18] , [19] , [20] , [21] , [22] . Confirmed case inputs for symptomatic and asymptomatic patients for each of the viral SARIs were also considered.…”

Section: Methodsmentioning

confidence: 99%

The economic burden of viral severe acute respiratory infections in the Kingdom of Saudi Arabia: A nationwide cost-of-illness study

Assiri,

Alsubaie,

Amer

et al. 2024

IJID Regions

View full text Add to dashboard Cite

Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention 2024 updated consensus on the prevention of respiratory syncytial virus

Alharbi,

Al-Hindi,

Alqwaiee

et al. 2024

Annals of Thoracic Medicine

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the major cause of bronchiolitis among children under 5 years of age worldwide, accounting for a prevalence of 25%–88% in Saudi Arabia. Although no effective treatment for the virus exists, passive immunoprophylaxis reduced RSV hospitalizations in high-risk children. With recent advances in immunization, the Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention panel screened recent relevant international guidelines, locally published data, and expert consensus to update guidelines for RSV prevention, taking into consideration the resources, timing, varying health profiles, and RSV burden in Saudi Arabia. The panel updated its recommendations to include immunization of infants, mothers, and older adults. Practical guidelines were prepared to facilitate the administration of the short-acting and newly developed long-acting RSV monoclonal antibodies (mAb) during the regular follow-ups of high-risk infants in specialized clinics. In addition, long-acting mAb was highlighted as all-infant protection in the routine immunization calendar.

show abstract

War against respiratory syncytial virus

Cited by 3 publications

References 21 publications

The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic

The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic

The economic burden of viral severe acute respiratory infections in the Kingdom of Saudi Arabia: A nationwide cost-of-illness study

Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention 2024 updated consensus on the prevention of respiratory syncytial virus

Contact Info

Product

Resources

About